




**CropLife**  
EUROPE

# Evolution of the paradigm for Environmental Risk Assessments

## CLE considerations - Part 2

Roman Ashauer  
Syngenta Fellow  
6 March 2024

# Early or late in the pipeline makes a difference



## Early stage drivers for *in-vitro* assays:




- Less test item needed
- Cheaper & faster
- Automation & throughput

## Late stage drivers for *in-vivo* assays:


- Definite regulatory endpoint (acceptance)
- No *in-vitro* to *in-vivo* extrapolation needed
- Species sensitivity differences & coverage

# Intra-species *in-vitro* to *in-vivo* toxicity extrapolation (IVIVE)

- Intra-species extrapolation, e.g. *in-vitro* to *in-vivo*
  - Typical approach to replace a certain standard test
  - Often involves *in-vitro* assays from the species of interest (e.g. fish cell lines to predict fish endpoints)
  - Combined with modelling to account for partitioning, toxicokinetics & toxicodynamics




Rainbow trout gill cells.  
Photo credit: Vivian Lu Tan/Eawag




Rainbow trout.  
<http://underwater-fish.blogspot.co.uk>

# Inter-species toxicity extrapolation & ecology

- **Inter-species** extrapolation (e.g. from standard test species to untested or endangered species) & ecology
  - Modelling for toxicokinetics & toxicodynamics, species traits, physiology, ecology, populations, landscapes
  - Can benefit from AOPs, but is conservation of MIE & pathways known in both species (tested & predicted)?
  - Are we more interested in cases where pathways are conserved or when they are not?!



# How to build a model (e.g. qAOP): scales



220 *The role of biomarkers in environmental assessment*





Figure 10.5 Linkages between biochemical, physiological, individual and population responses to pollutants.

We need better understanding of scale transitions & Carefully decide what to include in qAOPs

- Different time scales and different system sizes matter!
- Scale transitions are inherently difficult to model

# How to build a model (e.g. qAOP): complexity




As simple as possible  
&  
As complex as needed!


Guiding principles for building qAOPs: Perkins, E.J., et al., *Building and Applying Quantitative Adverse Outcome Pathway Models for Chemical Hazard and Risk Assessment. Environmental Toxicology and Chemistry*, 2019. 38(9): p. 1850-1865.

# Examples of very simple & successful «1 step» qAOPs

Species	Measured <i>in-vitro</i>	Predicted <i>in-vivo</i>	Modelling	Reference
Fish	Gill cell proliferation	Fish growth	Partitioning, PBK & van Bertalanffy growth	Stadnicka-Michalak, J., K. Schirmer and R. Ashauer, <i>Toxicology across scales: Cell population growth in vitro predicts reduced fish growth. Science Advances</i> , 2015. 1(7): p. 1-8.
Fish & birds	AHR activation	Early life-stage mortality	Exposure normalised to concentrations in eggs	Doering, J.A., S. Wiseman, J.P. Giesy and M. Hecker, <i>A Cross-species Quantitative Adverse Outcome Pathway for Activation of the Aryl Hydrocarbon Receptor Leading to Early Life Stage Mortality in Birds and Fishes. Environmental Science &amp; Technology</i> , 2018. 52(13): p. 7524-7533.
Birds	Embryo weight & length in egg injection study	Effects on hatchling and 14-day chick weight	PBK & DEB-TKTD	Martin, T., et al., <i>Reproductive toxicity in birds predicted by physiologically-based kinetics and bioenergetics modelling. Science of The Total Environment</i> , 2024. 912: p. 169096.



qAOP in Doering et al. 2018



qAOP in Martin et al. 2024

# Critical success factors for NG ERA

**Ecotox  
differs from  
human tox.**



**Create ERA  
specific  
problem  
definition.**

**The  
question  
dictates the  
model.**



**Include  
modellers  
from the  
start.**

**The model  
dictates the  
data needs.**






**Ensure data  
addresses  
modelling  
needs.**


# Bonus slides




# Will ecotoxicology become a truly predictive science?

	Physical chemistry	(Eco)toxicology
Macroscopic scale	 <p>Perfect gas  <math>p \times V = \text{constant}</math>                      (Boyle's law)</p>	 <p>Generic organism  <math>\text{stress} = 1/C_T \times \max(0, C_V - C_0)</math>                      (DEBtox)</p>
Molecular scale	 <p><b>Emerges</b></p> <p>Kinetic model of gases</p> <ul style="list-style-type: none"> <li>• Random motion</li> <li>• Ignore size</li> <li>• Elastic collisions only</li> </ul>	 <p><b>Missing theory</b></p> <p>Cellular pathways</p> <ul style="list-style-type: none"> <li>• Reaction networks</li> <li>• -omics</li> <li>• Pathway models</li> </ul>

# DEB-TKTD as link between AOPs & ERA?




# How to build a model (e.g. qAOP): scales



Ankley et al.  
AOPs ...  
*Environ. Toxicol. Chem.*  
**2010**, 29



Kramer et al.  
AOPs & ERA ...  
*ET&C* **2011**, 30




Wittwehr et al. ... *Toxicol. Sci.* **2016**, 155

We need better understanding  
of scale transitions  
&  
Carefully decide what to  
include in qAOPs

- Different time scales and different system sizes matter!
- Scale transitions are inherently difficult to model

# How to build a model (e.g. qAOP): complexity



As simple as possible  
&  
As complex as needed!

Guiding principles for building qAOPs: Perkins, E.J., et al., *Building and Applying Quantitative Adverse Outcome Pathway Models for Chemical Hazard and Risk Assessment. Environmental Toxicology and Chemistry*, 2019. 38(9): p. 1850-1865.



For more information  
Roman Ashauer  
[roman.ashauer@syngenta.com](mailto:roman.ashauer@syngenta.com)